ValiRx plc (GB:VAL) has released an update.
ValiRx Plc, a life science firm specializing in cancer therapeutics and women’s health, announced a partnership between its subsidiary Inaphaea BioLabs and BioReperia AB, a Swedish research organization. Inaphaea will provide Patient Derived Cells for BioReperia’s ZTX® platform, focusing initially on glioblastoma models for commercial services. The agreement includes an upfront fee, service royalties for Inaphaea, and the possibility of extension after the initial 12-month period.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
